These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 31580666)

  • 1. Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D
    Fyfe TJ; Kellam B; Sykes DA; Capuano B; Scammells PJ; Lane JR; Charlton SJ; Mistry SN
    J Med Chem; 2019 Nov; 62(21):9488-9520. PubMed ID: 31580666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The fast-off hypothesis revisited: A functional kinetic study of antipsychotic antagonism of the dopamine D2 receptor.
    Sahlholm K; Zeberg H; Nilsson J; Ögren SO; Fuxe K; Århem P
    Eur Neuropsychopharmacol; 2016 Mar; 26(3):467-76. PubMed ID: 26811292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D
    Sykes DA; Moore H; Stott L; Holliday N; Javitch JA; Lane JR; Charlton SJ
    Nat Commun; 2017 Oct; 8(1):763. PubMed ID: 28970469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D
    Free RB; Cuoco CA; Xie B; Namkung Y; Prabhu VV; Willette BKA; Day MM; Sanchez-Soto M; Lane JR; Laporte SA; Shi L; Allen JE; Sibley DR
    Mol Pharmacol; 2021 Oct; 100(4):372-387. PubMed ID: 34353882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent haloperidol derivatives covalently binding to the dopamine D2 receptor.
    Schwalbe T; Kaindl J; Hübner H; Gmeiner P
    Bioorg Med Chem; 2017 Oct; 25(19):5084-5094. PubMed ID: 28666858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Slow dissociation of partial agonists from the D₂ receptor is linked to reduced prolactin release.
    Carboni L; Negri M; Michielin F; Bertani S; Fratte SD; Oliosi B; Cavanni P
    Int J Neuropsychopharmacol; 2012 Jun; 15(5):645-56. PubMed ID: 21733233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of dopamine D1/D2 receptor complex is involved in the function of haloperidol in cardiac H9c2 cells.
    Lencesova L; Szadvari I; Babula P; Kubickova J; Chovancova B; Lopusna K; Rezuchova I; Novakova Z; Krizanova O; Novakova M
    Life Sci; 2017 Dec; 191():186-194. PubMed ID: 29054453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unique effect of clozapine on adenosine A
    Valle-León M; Casajuana-Martin N; Del Torrent CL; Argerich J; Gómez-Acero L; Sahlholm K; Ferré S; Pardo L; Ciruela F
    Biomed Pharmacother; 2023 Apr; 160():114327. PubMed ID: 36736280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer.
    Bonaventura J; Navarro G; Casadó-Anguera V; Azdad K; Rea W; Moreno E; Brugarolas M; Mallol J; Canela EI; Lluís C; Cortés A; Volkow ND; Schiffmann SN; Ferré S; Casadó V
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):E3609-18. PubMed ID: 26100888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The differential actions of clozapine and other antipsychotic drugs on the translocation of dopamine D2 receptors to the cell surface.
    Schrader JM; Irving CM; Octeau JC; Christian JA; Aballo TJ; Kareemo DJ; Conti J; Camberg JL; Lane JR; Javitch JA; Kovoor A
    J Biol Chem; 2019 Apr; 294(14):5604-5615. PubMed ID: 30670597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and evaluation of metabolism-based analogues of haloperidol incapable of forming MPP+-like species.
    Lyles-Eggleston M; Altundas R; Xia J; Sikazwe DM; Fan P; Yang Q; Li S; Zhang W; Zhu X; Schmidt AW; Vanase-Frawley M; Shrihkande A; Villalobos A; Borne RF; Ablordeppey SY
    J Med Chem; 2004 Jan; 47(3):497-508. PubMed ID: 14736232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Thieno[2,3- d]pyrimidine Scaffold Is a Novel Negative Allosteric Modulator of the Dopamine D
    Fyfe TJ; Zarzycka B; Lim HD; Kellam B; Mistry SN; Katrich V; Scammells PJ; Lane JR; Capuano B
    J Med Chem; 2019 Jan; 62(1):174-206. PubMed ID: 29683325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications.
    Lahti RA; Evans DL; Stratman NC; Figur LM
    Eur J Pharmacol; 1993 Jun; 236(3):483-6. PubMed ID: 8102973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.
    Langlois X; Megens A; Lavreysen H; Atack J; Cik M; te Riele P; Peeters L; Wouters R; Vermeire J; Hendrickx H; Macdonald G; De Bruyn M
    J Pharmacol Exp Ther; 2012 Jul; 342(1):91-105. PubMed ID: 22490380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors.
    Seeman P; Tallerico T
    Mol Psychiatry; 1998 Mar; 3(2):123-34. PubMed ID: 9577836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects.
    Wager TT; Chappie T; Horton D; Chandrasekaran RY; Samas B; Dunn-Sims ER; Hsu C; Nawreen N; Vanase-Frawley MA; O'Connor RE; Schmidt CJ; Dlugolenski K; Stratman NC; Majchrzak MJ; Kormos BL; Nguyen DP; Sawant-Basak A; Mead AN
    ACS Chem Neurosci; 2017 Jan; 8(1):165-177. PubMed ID: 27715007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
    Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I
    Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The action of a negative allosteric modulator at the dopamine D
    Draper-Joyce CJ; Verma RK; Michino M; Shonberg J; Kopinathan A; Klein Herenbrink C; Scammells PJ; Capuano B; Abramyan AM; Thal DM; Javitch JA; Christopoulos A; Shi L; Lane JR
    Sci Rep; 2018 Jan; 8(1):1208. PubMed ID: 29352161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.